VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | bb21217: next gen anti-BCMA CAR-T for R/R MM

Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, gives an update on the results from an ongoing phase I clinical study (CRB-402; NCT03274219) of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in heavily pretreated relapsed/refractory multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter